Tepotinib Phase II in Non-small Cell Lung Cancer (NSCLC) Harboring MET Alterations (Q66396531)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Tepotinib Phase II in Non-small Cell Lung Cancer (NSCLC) Harboring MET Alterations |
clinical trial |
Statements
VISION (English)
0 references
A Phase II, Single-arm Trial to Investigate Tepotinib in Advanced ( Stage IIIB/IV) Non-small Cell Lung Cancer With MET-exon-14 (METex14) Skipping Alterations or MET Amplification (VISION) (English)
0 references
13 September 2016
0 references
25 June 2019
0 references
120
0 references
18 year
0 references